S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
S&P 5005,963+0.54%
NASDAQ21,443+0.87%
DOW43,892+0.31%
DAX23,888+0.44%
FTSE 1008,721-0.12%
EUR/USD1.1465+0.07%
GBP/USD1.3220+0.14%
USD/JPY161.31-0.03%
Gold3,241+0.22%
WTI Oil76.40+0.81%
Bitcoin103,241+1.43%
10Y UST4.47%-9bp
MarketsFN
Home/Hedge Funds/Baker Bros Advisors/Q1 2023

Baker Bros Advisors

Period: Q1 2023 Β· Filed: 2023-05-15
View on SEC EDGAR β†—
AUM
$18.38B
Total portfolio value
Positions
105
Reported securities
Top Holding
SGEN
51.7% $9.50B
QoQ Changes
+7 / -8
new Β· exited
⚠️13F Filing Disclosure

AUM figures shown are calculated by summing the reported market value of all positions in SEC 13F-HR filings β€” not the fund's actual assets under management.

  • Excludes cash, bonds, private equity, short positions, and foreign-listed stocks not required to be reported.
  • For PUT and CALL options, the reported Value is the notional value of the underlying shares β€” not the option premium paid. This significantly overstates the actual capital at risk.
  • Actual fund AUM is typically higher and includes strategies, instruments, and positions that never appear in a 13F.
  • 13F filings cover institutional managers with β‰₯$100M in 13F securities. Positions reflect end-of-quarter holdings, disclosed up to 45 days after the period ends.

Data sourced from SEC EDGAR. This tracker is for informational purposes only and does not constitute investment advice.

Portfolio Holdings

Top 30 positions

⚠️ Performance % calculated from filing date ( 2023-05-15) shown is the underlying stock price movement β€” not the derivative's P&L.
TickerIssuerNotionalPort %@ FilingNow (EOD)Since FilingAllocation
SGENSeagen Inc.$9.50B51.68%β€”β€”
51.7%
INCYIncyte Corporation$2.61B14.22%$72.27$116.86+61.7%
14.2%
ONCBeiGene, Ltd.$2.52B13.68%$215.53$297.65+38.1%
13.7%
ACADACADIA Pharmaceuticals Inc.$789.3M4.29%$18.82$25.97+38.0%
4.3%
MDGLMadrigal Pharmaceuticals, Inc.$374.3M2.04%$242.26$528.10+118.0%
2.0%
BMRNBioMarin Pharmaceutical Inc.$370.5M2.02%$97.24$58.99-39.3%
2.0%
IMCRImmunocore Holdings plc$124.6M0.68%$49.44$32.50-34.3%
0.7%
RYTMRhythm Pharmaceuticals, Inc.$115.9M0.63%$17.84$114.17+540.0%
0.6%
KODKodiak Sciences Inc.$107.3M0.58%$6.20$38.54+521.6%
0.6%
BCRXBioCryst Pharmaceuticals, Inc.$106.0M0.58%$8.34$9.84+18.0%
0.6%
ARGXargenx SE$104.4M0.57%$372.58$939.68+152.2%
0.6%
AKROAkero Therapeutics, Inc.$90.6M0.49%β€”β€”
0.5%
KYMRKymera Therapeutics, Inc.$85.3M0.46%$29.63$113.51+283.1%
0.5%
REPLReplimune Group, Inc.$80.8M0.44%$17.66$11.58-34.4%
0.4%
ABCLAbCellera Biologics Inc.$78.8M0.43%$7.54$8.11+7.6%
0.4%
SWTXSpringWorks Therapeutics, Inc.$70.9M0.39%β€”β€”
0.4%
TRDAEntrada Therapeutics, Inc.$70.5M0.38%$14.50$7.72-46.8%
0.4%
BMEABiomea Fusion, Inc.$65.4M0.36%$31.01$1.41-95.5%
0.4%
RVMDRevolution Medicines, Inc.$58.3M0.32%$21.66$189.24+773.7%
0.3%
PRLDPrelude Therapeutics Inc.$57.7M0.31%$5.70$4.91-13.9%
0.3%
MRTXMirati Therapeutics, Inc.$52.4M0.29%β€”β€”
0.3%
FGENFibroGen, Inc.$49.2M0.27%β€”β€”
0.3%
CERSCerus Corporation$47.7M0.26%$2.97$3.16+6.4%
0.3%
IGMSIGM Biosciences, Inc.$43.4M0.24%β€”β€”
0.2%
AVTEAerovate Therapeutics, Inc.$39.6M0.22%β€”β€”
0.2%
IMTXImmatics N.V.$35.8M0.19%$6.90$9.95+44.2%
0.2%
ROIVRoivant Sciences Ltd.$35.3M0.19%$7.38$35.13+376.0%
0.2%
NRIXNurix Therapeutics, Inc.$34.5M0.19%$8.88$23.97+169.9%
0.2%
KDNYChinook Therapeutics, Inc.$33.7M0.18%β€”β€”
0.2%
KNSAKiniksa Pharmaceuticals, Ltd.$30.1M0.16%$10.76$64.53+499.7%
0.2%

Quarter-on-Quarter Activity

Q1 2023 vs. Q4 2022

New Positions (7)

TickerIssuerNotional
BPMCBlueprint Medicines Corporation$15.0M
ALLOAllogene Therapeutics, Inc.$7.8M
MRSNMersana Therapeutics, Inc.$7.8M
GERNGeron Corporation$6.6M
SANASana Biotechnology, Inc.$6.5M
RLAYRelay Therapeutics, Inc.$4.7M
GLUEMonte Rosa Therapeutics, Inc.$2.9M

Exited Positions (8)

TickerIssuerNotional
ASNDAscendis Pharma A/S$605.1M
HZNPHorizon Therapeutics Public Ltd Co$110.3M
TVTXTravere Therapeutics, Inc.$25.8M
Insmed Incorporated$19.2M
CBAYCymaBay Therapeutics, Inc.$13.6M
ZYMEZymeworks Inc.$13.4M
ALTAltimmune, Inc.$10.8M
CINCCinCor Pharma, Inc.$9.9M

Increased (8)

TickerIssuerNotionalShares Ξ”Since Filing
INSMInsmed Incorporated$5.5M+1619.3%
LPTXLeap Therapeutics, Inc.$2.3M+1226.7%
RVMDRevolution Medicines, Inc.$53.0M+1111.2%+773.7%
SERASera Prognostics, Inc.$6.6M+787.6%
FATEFate Therapeutics, Inc.$7.3M+675.0%
ROIVRoivant Sciences Ltd.$29.5M+566.6%+376.0%
SMMTSummit Therapeutics Inc.$2.5M+215.2%
RNAMAvidity Biosciences, Inc.$5.8M+130.9%

Trimmed (7)

TickerIssuerNotionalShares Ξ”Since Filing
VORXXXXVor Biopharma Inc.$-6.3M-56.8%
IDYAIDEAYA Biosciences, Inc.$-18.9M-50.1%
BMRNBioMarin Pharmaceutical Inc.$-418.1M-50.0%-39.3%
KDNYChinook Therapeutics, Inc.$-32.7M-42.6%
DSGNDesign Therapeutics, Inc.$-3.5M-9.4%
VSTMXXXXVerastem, Inc.$-0.3M-5.4%
AVTEAerovate Therapeutics, Inc.$-18.3M-0.7%
← Back to Hedge Funds